HealthCast: Here is the latest advance on Alzheimer’s disease

A new Fujirebio Diagnostics blood test identifies beta-amyloid, a brain plaque that is a key marker for Alzheimer’s disease.

The Food and Drug Administration cleared the test to replace PET scans and spinal fluid tests as the first stop for symptomatic patients 55 and older.

Alzheimer’s patients also have two new treatments to slow the progression: Leqembi and Kisunla, IV infusions that help clear the brain plaque.